A Study to Evaluate the Effectiveness and Safety of Tapentadol(CG5503) in the Treatment of Acute Pain After Hip Replacement Surgery Compared With Oxycodone and Placebo Followed by a Voluntary Open-Label Extension For Safety

NCT00364533 · clinicaltrials.gov ↗

PHASE3

Phase

TERMINATED

Status

367

Enrollment

INDUSTRY

Sponsor class

Stopped Slow enrollment

Conditions

Arthroplasty

Interventions

DRUG: Tapentadol IR (CG5503)
DRUG: Placebo
DRUG: Oxycodone HCL IR
DRUG: Tapentadol IR (CG5503)

Sponsor

Johnson & Johnson Pharmaceutical Research & Development, L.L.C.

Collaborators

[object Object]